Published in Ther Clin Risk Manag on April 01, 2008
Interventional studies for polycystic ovarian syndrome in children and adolescents. Ped Health (2010) 0.81
Myo-Inositol in the Treatment of Teenagers Affected by PCOS. Int J Endocrinol (2016) 0.76
An update on the management of acne vulgaris. Clin Cosmet Investig Dermatol (2009) 0.75
The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab (2004) 7.96
Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab (1998) 4.63
Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A (1998) 2.86
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception (2007) 2.44
Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem (1975) 1.75
Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) (1999) 1.60
New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv (2002) 1.21
Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception (2003) 1.13
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab (2000) 1.07
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab (2004) 0.98
Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod (2006) 0.95
Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception (1990) 0.95
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab (2003) 0.94
A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab (1999) 0.92
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab (2000) 0.91
Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than to changes in adrenocortical steroid secretion. Scand J Clin Lab Invest (2002) 0.91
Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril (2002) 0.89
Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril (2007) 0.88
Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update (2005) 0.88
Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril (2006) 0.87
Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab (1995) 0.86
Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand (1995) 0.85
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod (2002) 0.85
An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care (2004) 0.84
Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol (1991) 0.84
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception (2006) 0.83
Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care (2007) 0.83
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Hum Reprod (2004) 0.83
The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab (1997) 0.82
Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Hum Reprod (2002) 0.81
Androgens in polycystic ovarian syndrome. Ann N Y Acad Sci (1993) 0.80
Combined oral contraceptive treatment of adolescent girls with polycystic ovary syndrome. Lipid profile. Ann N Y Acad Sci (2000) 0.78
Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod (1998) 0.78
Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril (2000) 0.78
Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol (Oxf) (1991) 0.77
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. QJM (2001) 0.77
Choice of treatment for women with polycystic ovary syndrome. Fertil Steril (2006) 0.77
[In vivo studies on metabolism of androgens following administration of steroid inhibitors of ovulation. 1. Changes in the secretion of androgens and excretion of their metabolites in normal subjects and women with the Stein-Leventhal syndrome]. Acta Endocrinol (Copenh) (1965) 0.76
Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 3.80
Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab (2006) 3.46
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol (2011) 3.02
Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 2.28
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 2.11
Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol (2008) 1.92
Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril (2005) 1.82
Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab (2006) 1.56
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril (2002) 1.55
Laparoscopic evaluation following failure to achieve pregnancy after ovulation induction with clomiphene citrate. Fertil Steril (2003) 1.51
Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet (2011) 1.51
The severity of menstrual dysfunction as a predictor of insulin resistance in PCOS. J Clin Endocrinol Metab (2013) 1.50
Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril (2008) 1.49
Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 1.44
Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question. Maturitas (2010) 1.39
Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. BJU Int (2011) 1.39
Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril (2005) 1.34
Socioeconomic and racial predictors of undergoing laparoscopic hysterectomy for selected benign diseases: analysis of 341487 hysterectomies. J Minim Invasive Gynecol (2008) 1.33
Visually scoring hirsutism. Hum Reprod Update (2009) 1.21
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab (2006) 1.19
Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol (2004) 1.18
Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol (2010) 1.17
Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2005) 1.17
miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Diabetes (2013) 1.17
FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS One (2011) 1.16
Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab (2006) 1.13
Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity. PLoS One (2011) 1.12
Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril (2009) 1.10
The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord (2007) 1.09
Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol (2007) 1.08
Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 1.06
Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.06
From the eye of the nurses: 360-degree evaluation of residents. J Contin Educ Health Prof (2009) 1.04
Congenital adrenal hyperplasia. J Pediatr Adolesc Gynecol (2011) 1.03
Diagnosis, phenotype, and prevalence of polycystic ovary syndrome. Fertil Steril (2006) 1.03
Defining hirsutism in Chinese women: a cross-sectional study. Fertil Steril (2011) 1.01
Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation. Fertil Steril (2009) 1.01
Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab (2013) 1.01
Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One (2011) 1.00
Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt) (2009) 1.00
Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil Steril (2006) 1.00
Reanalyzing the modified Ferriman-Gallwey score: is there a simpler method for assessing the extent of hirsutism? Fertil Steril (2011) 0.97
Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.96
Degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS. Fertil Steril (2008) 0.96
Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril (2006) 0.95
The age-associated decline of androgens in reproductive age and menopausal Black and White women. J Clin Endocrinol Metab (2007) 0.95
Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.94
Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril (2011) 0.94
A Summary of the Endocrine Society Clinical Practice Guidelines on Congenital Adrenal Hyperplasia due to Steroid 21-Hydroxylase Deficiency. Int J Pediatr Endocrinol (2010) 0.94
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab (2005) 0.93
Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab (2008) 0.93
The Associations Between Residents' Behavior and the Thomas-Kilmann Conflict MODE Instrument. J Grad Med Educ (2010) 0.93
First evidence of genetic association between AKT2 and polycystic ovary syndrome. Diabetes Care (2008) 0.93
Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab (2012) 0.92
Further investigation in europeans of susceptibility variants for polycystic ovary syndrome discovered in genome-wide association studies of Chinese individuals. J Clin Endocrinol Metab (2015) 0.92
Laser hair reduction in the hirsute patient: a critical assessment. Hum Reprod Update (2002) 0.91
Adrenal function during childhood and puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 0.91
A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. Menopause (2012) 0.90
Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17beta-hydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab (2009) 0.90
DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab (2010) 0.89
Diagnosing the diagnosis: why we must standardize the defining features of polycystic ovary syndrome. Ann Clin Biochem (2008) 0.89
Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril (2005) 0.89
Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril (2008) 0.89
Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril (2006) 0.89
Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS. Clin Endocrinol (Oxf) (2013) 0.89
Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome. Fertil Steril (2007) 0.88
Negative association between androgen receptor gene CAG repeat polymorphism and polycystic ovary syndrome? A systematic review and meta-analysis. Mol Hum Reprod (2012) 0.87
Type 2 diabetes susceptibility single-nucleotide polymorphisms are not associated with polycystic ovary syndrome. Fertil Steril (2011) 0.86
Heritability of dehydroepiandrosterone sulfate in women with polycystic ovary syndrome and their sisters. Fertil Steril (2006) 0.86
Guidelines for the Development of Comprehensive Care Centers for Congenital Adrenal Hyperplasia: Guidance from the CARES Foundation Initiative. Int J Pediatr Endocrinol (2011) 0.86
Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome. Fertil Steril (2004) 0.86
Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril (2004) 0.86
The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol (2004) 0.84
Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin Endocrinol Metab (2002) 0.83
Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer. Clin Endocrinol (Oxf) (2014) 0.83
Promoting residents' professional development and academic productivity using a structured faculty mentoring program. Teach Learn Med (2010) 0.83
Metabolic and cardiovascular genes in polycystic ovary syndrome: a candidate-wide association study (CWAS). Steroids (2011) 0.83
Regulation of adiponectin secretion by adipocytes in the polycystic ovary syndrome: role of tumor necrosis factor-{alpha}. J Clin Endocrinol Metab (2010) 0.83
Socioeconomic status and polycystic ovary syndrome. J Womens Health (Larchmt) (2011) 0.83
Effect of oral estrogen on substrate utilization in postmenopausal women. Fertil Steril (2007) 0.83
Stability of adrenocortical steroidogenesis over time in healthy women and women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 0.83
Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 0.83
Correlation of adrenocorticotropin steroid levels between women with polycystic ovary syndrome and their sisters. Am J Obstet Gynecol (2007) 0.82
Family size in women with polycystic ovary syndrome. Fertil Steril (2006) 0.82
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab (2003) 0.82
Effect of insulin and testosterone on androgen production and transcription of SULT2A1 in the NCI-H295R adrenocortical cell line. Fertil Steril (2008) 0.81
Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome. Hum Reprod (2014) 0.81
Reproducibility of the adrenal androgen response to adrenocorticotropic hormone stimulation. Fertil Steril (2006) 0.81
The relationship of menopausal status and rapid menopausal transition with carotid intima-media thickness progression in women: a report from the Los Angeles Atherosclerosis Study. J Clin Endocrinol Metab (2010) 0.81
Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril (2004) 0.81
The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril (2009) 0.80
Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility. J Clin Endocrinol Metab (2012) 0.80
Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 0.80
Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci (2009) 0.79
Polycystic ovary syndrome is a family affair. J Clin Endocrinol Metab (2008) 0.79
Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertil Steril (2002) 0.79
Effects of endogenous androgens and abdominal fat distribution on the interrelationship between insulin and non-insulin-mediated glucose uptake in females. J Clin Endocrinol Metab (2013) 0.79
Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. Fertil Steril (2009) 0.79
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. Fertil Steril (2009) 0.79